ENFLEUR is pleased to report that Canadian cannabis producer Canopy Growth has announced a clinical research deal with the NEEKA Health Canada, and National Hockey League’s Alumni Association. The purpose of the one-year study is to investigate the therapeutic activity of cannabinoids in the treatment of a range of neurological conditions that develop as a result of past concussions:
– Progressive dementia from chronic traumatic encephalopathy (CTE)
– Depression
– Post-traumatic stress disorders (PTSD)
– Functional disintegration, a disorder characterized by debilitating limitations in coping with one’s environment
CBD, a non-psychoactive cannabinoid, has been targeted owing to its reported therapeutic use in the treatment of inflammation, depression, PTSD, stress, and chronic pain. It has also been investigated for its neuroprotective effects.
“This complex and multidimensional study will give us an unprecedented understanding of the interaction between cannabidiol (CBD) and the brains and behaviours of former NHL players live with post-concussion symptoms,” said Dr. Mark Ware, Chief Medical Officer, Canopy Growth.
Studies such as these can only clarify the therapeutic potential of cannabis derivatives in the treatment of life interrupting conditions. Owing to CBD’s recent popularity as a novel therapy in the treatment of a wide range of conditions, its popularity on a currently unregulated market has also risen. If considering supplementing a wellness routine with CBD, the quality and transparency of the product is paramount.